Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Intranasal Olcegepant in Healthy Volunteers
NCT02194322Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2001
- Primary completion
- Jan 2002
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial in migraine comparing BIBN 4096 BS with Placebo (2 arms). Primary endpoints: Number of patients with adverse events up to 24 days, Number of patients with abnormal changes in laboratory parameters up to 24 days and 5 more. Started Nov 2001; status: completed.
02
Drugs
olcegepant
03
Conditions
migraine
Beyond the preview
Go deeper on NCT02194322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02194322.